Literature DB >> 9456248

Correspondence re: G. C. Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol., Biomark. Prev., 6: 505-509, 1997.

W Zheng, L Dunning, F Jin, J Holtzman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9456248

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


× No keyword cloud information.
  9 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

2.  Circulating estrogen metabolites and risk of breast cancer in postmenopausal women.

Authors:  Alan A Arslan; Karen L Koenig; Per Lenner; Yelena Afanasyeva; Roy E Shore; Yu Chen; Eva Lundin; Paolo Toniolo; Göran Hallmans; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

3.  Circulating estrogen metabolites and risk for breast cancer in premenopausal women.

Authors:  Alan A Arslan; Roy E Shore; Yelena Afanasyeva; Karen L Koenig; Paolo Toniolo; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08       Impact factor: 4.254

4.  3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study.

Authors:  Shilpi Rajoria; Robert Suriano; Perminder Singh Parmar; Yushan Lisa Wilson; Uchechukwu Megwalu; Augustine Moscatello; H Leon Bradlow; Daniel W Sepkovic; Jan Geliebter; Stimson P Schantz; Raj K Tiwari
Journal:  Thyroid       Date:  2011-01-22       Impact factor: 6.568

5.  The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.

Authors:  Dina Nikitina; Marcia Llacuachaqui; Daniel Sepkovic; H Leon Bradlow; Steven A Narod; Joanne Kotsopoulos
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

6.  Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women.

Authors:  A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

7.  Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women.

Authors:  A Heather Eliassen; Regina G Ziegler; Bernard Rosner; Timothy D Veenstra; John M Roman; Xia Xu; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

8.  Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16α-hydroxyestrone ratio predictive for breast cancer?

Authors:  Nadia Obi; Alina Vrieling; Judith Heinz; Jenny Chang-Claude
Journal:  Int J Womens Health       Date:  2011-02-08

9.  The Steroid Metabolome and Breast Cancer Risk in Women with a Family History of Breast Cancer: The Novel Role of Adrenal Androgens and Glucocorticoids.

Authors:  Lauren C Houghton; Renata E Howland; Ying Wei; Xinran Ma; Rebecca D Kehm; Wendy K Chung; Jeanine M Genkinger; Regina M Santella; Michaela F Hartmann; Stefan A Wudy; Mary Beth Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-30       Impact factor: 4.090
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.